A novel approach to quinazolin-4(3H)-one via quinazoline oxidation: an improved synthesis of 4-anilinoquinazolines

FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets

Martin H. Cohen, Grant A. Williams, Rajeshwari Sridhara et al. · The Oncologist · 2003 · 577 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +10

Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure−Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor

Alexander J. Bridges, Hairong Zhou, Donna R. Cody et al. · Journal of Medicinal Chemistry · 1996 · 322 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Novel 4-Anilinoquinazolines with C-7 Basic Side Chains:  Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors

Laurent Hennequin, Elaine S. E. Stokes, Andrew P. Thomas et al. · Journal of Medicinal Chemistry · 2002 · 308 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase

Ji-Quan Wang, Mingzhang Gao, Kathy D. Miller et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 96 citations

Medicine, Nuclear Medicine, Oncology +12

Improved Synthesis of Substituted 6,7-Dihydroxy-4-quinazolineamines: Tandutinib, Erlotinib and Gefitinib

Petr Knesl, Dirk Röseling, Ulrich Jordis · Molecules · 2006 · 61 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +6